Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Fiche publication
Date publication
août 2019
Journal
Lung cancer (Amsterdam, Netherlands)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MENNECIER Bertrand, Dr SCHOTT Roland
Tous les auteurs :
Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C
Lien Pubmed
Résumé
Brigatinib is a next-generation ALK inhibitor initially developed in ALK-positive NSCLC pretreated with crizotinib.
Mots clés
ALK inhibitor, ALK rearrangement, Advanced non-small cell lung cancer, Brigatinib, Crizotinib, Early access program
Référence
Lung Cancer. 2019 Aug 14;136:109-114